Kim Yon Su, Yang Seung Hee, Kang Hee Gyung, Seong Eun Young, Lee Se Han, Gao Wenda, Kenny James, Zheng Xin Xiao, Strom Terry B
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Int Immunol. 2006 Dec;18(12):1771-7. doi: 10.1093/intimm/dxl111. Epub 2006 Oct 26.
Dendritic cells (DCs) are pivotal antigen-presenting cells and serve a unique role in initiating immunity. To test the hypothesis that pre-immunization of recipient with certain DC subsets of donor origin can influence graft outcome, we have studied the effects of immunization with allogeneic CD4(+)CD8(-)CD11c(+) dendritic cell (CD4(+)DC) and CD4(-)CD8(+)CD11c(+) dendritic cell (CD8(+)DC) on the allograft response. Although both immature CD4(+)DC and CD8(+)DC subsets from DBA/2 were able to prime naive allogeneic C57BL/6 (B6) T cells in mixed lymphocyte reaction (MLR), CD8(+)DC exerted more vigorous alloimmune responses than CD4(+)DC did. Also, CD4(+)DC-driven allogeneic T cell response was attenuated more significantly by anti-CD154 mAb than CD8(+)DC-driven response. Consistent with the MLR results, combined pre-treatment with CD4(+)DC, but not CD8(+)DC, plus anti-CD154 mAb produced donor strain-specific long-term graft survival and induced tolerance while treatment with CD8(+)DC plus anti-CD154 mAb created minimal prolongation of allograft survival in a pancreas islet transplant model (DBA/2-->B6). The beneficial effects exerted by CD4(+)DC and anti-CD154 mAb pre-treatment were correlated with T(h)1 to T(h)2 immune deviation and with the amplified donor-specific suppressive capacity by recipient CD4(+)CD25(+) T cells. These findings highlight the capacity of CD4(+)DC to modulate alloimmune responses, and suggest therapeutic approaches for the induction of donor-specific tolerance.
树突状细胞(DCs)是关键的抗原呈递细胞,在启动免疫反应中发挥独特作用。为了验证受体预先接种供体来源的某些DC亚群会影响移植物结局这一假说,我们研究了用同种异体CD4(+)CD8(-)CD11c(+)树突状细胞(CD4(+)DC)和CD4(-)CD8(+)CD11c(+)树突状细胞(CD8(+)DC)进行免疫对同种异体移植反应的影响。尽管来自DBA/2的未成熟CD4(+)DC和CD8(+)DC亚群在混合淋巴细胞反应(MLR)中均能够激活同种异体C57BL/6(B6)幼稚T细胞,但CD8(+)DC引发的同种免疫反应比CD4(+)DC更强。此外,抗CD154单克隆抗体对CD4(+)DC驱动的同种异体T细胞反应的抑制作用比CD8(+)DC驱动的反应更显著。与MLR结果一致,在胰腺胰岛移植模型(DBA/2→B6)中,联合使用CD4(+)DC而非CD8(+)DC加抗CD154单克隆抗体进行预处理可产生供体菌株特异性的长期移植物存活并诱导耐受,而使用CD8(+)DC加抗CD154单克隆抗体进行治疗对同种异体移植存活的延长作用极小。CD4(+)DC和抗CD154单克隆抗体预处理所产生的有益效果与Th1向Th2免疫偏移以及受体CD4(+)CD25(+)T细胞增强的供体特异性抑制能力相关。这些发现突出了CD4(+)DC调节同种免疫反应的能力,并提示了诱导供体特异性耐受的治疗方法。